FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average bur	den						
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						it Company		134						1
Name and Address of Reporting Person*     Bunker Kevin D.	2. Issuer Name and Ticker or Trading Symbol Zentalis Pharmaceuticals, Inc. [ ZNTL ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify					
(Last) (First) (Mid C/O ZENTALIS PHARMACEUTICA 530 SEVENTH AVENUE, SUITE 220	3. Date of Earliest Transaction (Month/Day/Year) 10/01/2021								Chief Operating Officer					
(Street) NEW YORK NY 100	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)	)									reis	JII			
Table I	Non-Deriva	tive Secu	rities	Acqui	ired,	Dispose	ed of,	, or	Beneficia	ally Own	ed			
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)					5. Amou Securiti Benefic Owned Followi	ies cially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	Amount	(A) (D)	or	Price	Reporte Transac (Instr. 3	d tion(s)			ŕ
Common Stock	09/24/2021			G <sup>(1)</sup>	V	350	Ι	)	\$ <mark>0</mark>	995,	067(2)	D		
Common Stock	09/24/2021			G <sup>(1)</sup>	v	350	A	<b>A</b>	\$0	3	50	I	C	s UTMA astodian or sons
Common Stock	10/01/2021			<b>S</b> <sup>(3)</sup>		1,416	Ι	)	<b>\$</b> 64.7309 <sup>0</sup>	4) 7,	004	I		ee ootnote <sup>(5)</sup>
Common Stock	10/01/2021			S <sup>(3)</sup>		3,121	I	)	\$65.8002 <sup>0</sup>	6) 3,	883	I	1 1	ee ootnote <sup>(5)</sup>
Common Stock	10/01/2021			s <sup>(3)</sup>		3,679	I		\$66.8865 <sup>(</sup>	7) 2	04	I	- 1	ee ootnote <sup>(5)</sup>
Common Stock	10/01/2021			S <sup>(3)</sup>		204	I	)	<b>\$</b> 67.4449 <sup>0</sup>	449 <sup>(8)</sup> 0				ee ootnote <sup>(5)</sup>
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
ritle of vivative Conversion price of Exercise Price of Derivative Security		4. Transaction Code (Instr. 8) Securiti Acquire (A) or Disposs of (D) (Instr. 3 and 5)		Expiration Date (Month/Day/Year) ities red sed 3, 4			7. Title and Amount of Securities Underlying Derivative Security (Insti 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici: Owned Followin Reporter Transact (Instr. 4)	re O es ally D or g (I) d	vnership orm: rect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Evaluation of Decourses:		Code V	(A)		ate xercisa		ation	Title	Amount or Number of Shares					

- 1. Transfer to Reporting Person in his capacity as custodian for sons under Uniform Transfers to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
- $2.\ Includes\ 576\ shares\ acquired\ under\ the\ Zentalis\ Pharmaceuticals,\ Inc.\ 2020\ Employee\ Stock\ Purchase\ Plan\ on\ September\ 30,\ 2021.$
- 3. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020.
- 4. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$64.26 to \$65.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any.
- 6. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$65.29 to \$66.27. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 7. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$66.41 to \$67.34. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 8. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from \$67.44 to \$67.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

## Remarks:

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.